Blinatumoab公司
帕纳替尼
医学
嵌合抗原受体
肿瘤科
造血干细胞移植
CD19
临床试验
免疫学
内科学
移植
免疫疗法
抗体
酪氨酸激酶
免疫系统
达沙替尼
受体
作者
Nicholas J. Short,Hagop M. Kantarjian,Elias Jabbour
出处
期刊:Leukemia
[Springer Nature]
日期:2021-06-25
卷期号:35 (11): 3044-3058
被引量:30
标识
DOI:10.1038/s41375-021-01277-3
摘要
In the past decade, the available treatments for patients with acute lymphoblastic leukemia (ALL) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes. With the development of the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3-CD19 bispecific T-cell engager antibody blinatumomab, CD19 chimeric antigen receptor T-cell therapy, and the potent BCR-ABL1 tyrosine kinase inhibitor ponatinib, the outlook of ALL in both younger and older adults has substantially improved. The availability of highly effective drugs raised important questions concerning the optimal combination and sequence of these agents, their incorporation into frontline regimens, and the role of hematopoietic stem cell transplantation. In this review, we discuss the rapidly evolving paradigms in the treatment of ALL, highlighting both established and effective regimens, as well as promising new therapies that are being evaluated in ongoing clinical trials. We specifically focus on novel combination regimens in both the frontline and salvage settings that are leading to new standards of care in the treatment of ALL.
科研通智能强力驱动
Strongly Powered by AbleSci AI